Guest guest Posted March 15, 2005 Report Share Posted March 15, 2005 Always open for discussion -- I'm a **modeller** so I have no personal investment, rather prefer to improve the model... :-) ------------------------------------------------------------------ " 4 case reports by A.D.Hock (Germany) brought up the possibility that Vitamin D and parathormone disturbance should not be overlooked as a possible cause of chronic fatigue. The symptoms are very similar and this is a treatable disorder. " Source: http://www.cfsresearch.org/cfs/conferences/2nf.htm (Second World Congress on Chronic Fatigue Syndrome and Related Disorders) ----------------------------------------- Hack AD. Divalent Cations, Hormones, Psyche and Soma: Four Case Reports Journal of Chronic Fatigue Syndrome 2000; 6(3/4): 117 " Objectives: The steroid hormone, vitamin D and the peptide hormone, parathormone are reported to influence not only bone metabolism, but also other metabolic and nervous, cardiovascular and immune functions, and mood. Regular actions of these hormones depend highly on intracellular magnesium content. Although symptoms are recognized, they usually are not correlated to these hormones. Foregoing case studies have revealed that vitamin D and/or parathormone disorders are common causes of CFS-fibromyalgia like symptoms. Methods: Four patients with chronic fatigue-like symptoms and vitamin D (25OHD3) and parathormone (PTH intact) disorders are illustrated to demonstrate conflicting laboratory results. Patients were treated with 5,000 to 10,000 IU cholecalciferol, plus multiminerals and trace elements. Clinical outcome was assessed and treatment difficulties are reported. Results: Diagnostic pitfalls are shown. Vitamin D and parathormone disorders are not completely detectable by calcium and phosphate screening. In 2 of this 4 demonstrated cases treatable diagnosis would have been missed without endocrinological screening. In the case of undetected long-standing disorder of these hormones, intracellular mineral derangement follows, thus inducing vitamin D resistance and parathormone ineffectiveness which makes therapy difficult. Combining vitamin D therapy with multiminerals possibly may overcome these obstacles. Conclusions: Vitamin D and parathormone disturbance should not be overlooked in chronic fatigue. Appropriate therapy is easy, inexpensive and harmless. Early diagnosis and treatment might be essential to avoid chronic fatigue syndrome. The complexity of diagnosis, therapy and scientific background may lead to a new understanding of ``psycho-somatic'' disease. The relation between intracellular minerals, trace elements, cellular energy supply and responsible hormones should become clearer. " ------------------------- Hock, AD. Fatigue and 25-hydroxyvitamin D levels. Journal of Chronic Fatigue Syndrome, 1997, 3, 3, 117-127. This article describes 504 fatigued patients, of whom all but eleven had low levels of 25-hydroxyvitamin D. They were treated using appropriate doses of cholecalciferol. There was an excellent response in those with a mild deficiency, but a more variable outcome for patients with extremely low levels and/or chronic ill health. The author suggests that measurements of vitamin D should be included in the screening of patients with fatigue. http://freespace.virgin.net/david.axford/mecap97.htm > <>Hi Ken, > > > Thankyou for the pages. I have found them very useful. Would you be > interested in some constructive criticism/discussion on a few points? > > Also do you happen to have a copy of the paper: > > Hock, AD. *_Fatigue and 25-hydroxyvitamin D levels_*. Journal of Chronic > Fatigue Syndrome, 1997, 3, 3, 117-127. > > If so I would really appreciate a copy, if not a summary of findings? Is > fatigue a symptom of vit D deficiency. > > Regards, Blake Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.